Quoin Pharmaceuticals (QNRX) Profit After Tax (2021 - 2026)

Quoin Pharmaceuticals has reported Profit After Tax for 6 years, with the latest figure at -$5.0 million in Q1 2026.

• Quarterly Profit After Tax fell 31.1% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.9 million (down 62.21% YoY) and the FY2025 annual result came in at -$15.8 million, down 76.35% from the prior year.
• Profit After Tax retreated to -$5.0 million in Q1 2026 per QNRX's latest filing, from -$4.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$1.7 million in Q1 2022 and troughed at -$5.0 million in Q1 2026.
• A 5-year average of -$2.8 million and a median of -$2.3 million in 2024 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 83.07% in 2022, down 115.76% in 2022.
• Over 5 years, Profit After Tax stood at -$2.0 million in 2022, then slipped by 2.44% to -$2.0 million in 2023, then retreated by 12.75% to -$2.3 million in 2024, then sank by 86.27% to -$4.3 million in 2025, then decreased by 16.08% to -$5.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$5.0 million, -$4.3 million, and -$3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.